Vagustim Health Technologies LLC

Vagustim operates at the intersection of medical devices, neuroscience, and consumer wellness, with non-invasive auricular vagus nerve stimulation as its central product approach. Its portfolio ranges from the Vagustim v1, described as a portable device for home use, to the v1 Plus for expert and clinical use and the V2 generation with app support and AI-personalized sessions. The website-described differentiators include bilateral ear-based stimulation, adjustable settings, offline preset programs, and an app with guided sessions and wearable integrations such as Oura, Fitbit, and Garmin. These features give the offering a consumer-facing software and at-home-use emphasis alongside its stimulation hardware. Vagustim’s wellness framing and ear-applied product design distinguish its stated use case, while its clinical-oriented v1 Plus suggests an attempt to serve professional users as well. The company’s acceptance into AARP’s AgeTech Collaborative on Jun 30, 2026 adds an aging and healthy-longevity ecosystem connection, but does not by itself demonstrate clinical validation, distribution scale, or commercial traction.

Vagustim was founded in 2019 and announced a $150,000 pre-seed round on Feb 15, 2019, led by Eczacıbaşı Momentum, with Erman Turan also participating. No later financing round or valuation is identified, so the available funding history does not support a conclusion that the company has raised follow-on capital. Its product descriptions show a portfolio extending from Vagustim v1 and v1 Plus to replacement earsets, conductive gel, a mobile app, and Vagustim V2. The most clearly dated recent inflection point is the Jun 30, 2026 acceptance into AARP’s AgeTech Collaborative, which may provide access to ecosystem relationships and business development support relevant to healthy aging. The company is listed in an 11–50 employee band, while its current employee highlights identify two positions; these measures differ in scope and do not establish a hiring trend. Taken together, the evidence suggests product-line development and a new ecosystem connection, but leaves revenue, customer growth, hiring momentum, and the effect of the AARP program unquantified.